Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

IGC Pharma (IGC) Accumulated Depreciation & Amortization (2016 - 2025)

IGC Pharma (IGC) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $1.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a N/A change, with the full-year FY2025 number at $2.7 million, changed N/A from a year prior.
  • Accumulated Depreciation & Amortization was $1.7 million for Q3 2025 at IGC Pharma, down from $2.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.3 million in Q4 2021 to a low of $1.7 million in Q3 2025.
  • A 5-year average of $2.6 million and a median of $2.6 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 22.59% in 2021, then plummeted 39.88% in 2023.
  • IGC Pharma's Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then dropped by 2.42% to $3.2 million in 2022, then dropped by 27.73% to $2.3 million in 2023, then increased by 10.96% to $2.6 million in 2024, then tumbled by 33.73% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Accumulated Depreciation & Amortization are $1.7 million (Q3 2025), $2.8 million (Q2 2025), and $2.7 million (Q1 2025).